Latest Kaiser Health News Stories
Newsletter editor Brianna Labuskes, who reads everything on health care to compile our daily Morning Briefing, offers the best and most provocative stories for the weekend.
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
Sometimes a drug plan’s copayment is higher than the cash price, and under a little-known federal rule, pharmacists have to tell Medicare beneficiaries that — but only if they ask.
More health plans are refusing to count the copayment assistance offered by drug makers as part of the patients’ deductibles or out-of-pocket limits.
The drugmaker agreed to a settlement with the Justice Department over allegations that it funneled copay assistance money through a foundation to Medicare patients.
KHN’s Sarah Jane Tribble explains the key elements of the Trump blueprint on CBS News’ “Red & Blue.”
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.
Guess who’s back grabbing headlines? Pharmacy benefit managers — those companies that serve as middlemen in the prescription drug pipeline.
The first-in-the-nation measure would empower Vermont to set up a wholesale program to import prescription drugs from Canada. But it still will have to get federal buy-in before it is operational.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call discuss President Donald Trump’s proposals to control prescription drug prices and the efforts to sell the plan to lawmakers and the public. Also, Rovner interviews emeritus law professor Timothy Jost about the state of the Affordable Care Act.
President Donald Trump’s much-awaited speech about slashing drug costs was long on rhetoric but short on specifics that will reduce prices.
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Margot Sanger-Katz of The New York Times and Anna Edney of Bloomberg News discuss the latest on the politics of rising premiums, GOP efforts to take back money from the Children’s Health Insurance Program, and the controversy over new rules requiring calorie information on menus. Plus for extra credit, the panelists recommend their favorite health stories of the week.
Even voters who say they are more enthusiastic about voting in this congressional election than in past ones are not motivated by any specific issue. But, according to a poll out Thursday, health care policies rank high among topics voters want candidates to address.
Federal law prohibits them from using the coupons drugmakers offer to help patients cover their share of a medicine’s cost.
The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market.